Factors affecting pharmacokinetic variability of oral topotecan: a population analysis
Open Access
- 20 January 2004
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 90 (2), 343-347
- https://doi.org/10.1038/sj.bjc.6601469
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918Journal of Clinical Oncology, 2002
- Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumorsClinical Pharmacology & Therapeutics, 2002
- Individual adaptive dosing of topotecan in ovarian cancer.2002
- A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancerEuropean Journal Of Cancer, 2002
- Population pharmacokinetics of topotecan: intraindividual variability in total drugCancer Chemotherapy and Pharmacology, 2000
- TopotecanDrugs, 1999
- TopotecanDrugs, 1998
- Clinical Pharmacokinetics of TopotecanClinical Pharmacokinetics, 1996
- Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeksCancer Chemotherapy and Pharmacology, 1995
- The importance of modeling interoccasion variability in population pharmacokinetic analysesJournal of Pharmacokinetics and Biopharmaceutics, 1993